Vertex Pharmaceuticals: A Look At Their Pain Therapy Program
Vertex Pharmaceuticals is diversifying from its cystic fibrosis dominance into pain and other markets. Check out our recommendation for VRTX stock.
Investing Snacks2d
Vertex Dodges Market Mayhem With a Wink
Despite a market bloodbath that left the S&P 500 down 4.84%, Vertex Pharmaceuticals managed a modest gain of 0.11%, flaunting resilience. The biotech firm outpaced the broader medical sector over the ...
Wells Fargo Remains a Hold on Vertex Pharmaceuticals (VRTX)
Wells Fargo analyst Mohit Bansal maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report) yesterday and set a price target ...
Investing Snacks3d
Vertex Vibes: Analysts Crank Up the Heat
Vertex Pharmaceuticals has analysts doing financial backflips as they boost its price targets, with Royal Bank of Canada ...
InsuranceNewsNet4d
Proxy Statement (Form DEF 14A)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549. You are invited to attend the 2025 annual meeting of shareholders of HarborOne Bancorp, Inc., which will be held on May 13, ...
Fierce Biotech6d
Vertex abandons islet cell-device combo after failing to improve diabetes biomarker
Vertex is ending work on one of its two clinical-stage islet cell treatments after the diabetes therapy looked unlikely to ...